FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

Fate Therapeutics (FATE) reported a loss of 31 cents per share (excluding impairment loss) in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 44 cents. The company reported a loss of 45 cents per share in the year-ago period.Including the impairment loss of $14.7 million, loss per share was 44 cents.The company earned collaboration revenues of$1.9 million, surpassing the Zacks Consensus Estimate of $1 million. The figure also increased from$1.7 million reported in the y ...